Evaluation of medication errors in an infectious diseases ward of a teaching hospital in Iran
View/ Open
Date
2014Author
Hamishehkar, H
Khamechi, M
Naghili, B
Rezaee, H
Metadata
Show full item recordAbstract
Background: Medication errors (MEs) and adverse drug reactions (ADRs) are among the main causes of adverse events in hospitals, leading to disability and death in up to 6. 5% of hospital admissions. Application of appropriate measures for identifying medication errors and assessing potential adverse drug events are of clinical interest. Methods: This was an observational study performed in the infectious diseases ward of Imam Reza Hospital in Tabriz during the July 2013 to March 2014. Medical files and drug charts of 200 patients were reviewed, and errors in physician and nursing levels were determined. For detecting medication errors, treatment regimens of patients were evaluated, and then compared with the standard practice guidelines and drug references. Presence of any incompatibilities were considered as MEs. Results: During the study period, 126 MEs (0.63 errors per patient) were detected, occurring as incorrect time (38. 1%), incorrect dose (29. 37%), omission (11. 9%), administration error (9. 52%), incorrect dosage form (4. 76%), incorrect drug (2. 38%) and incorrect route (3. 97%). Physicians and nurses were responsible for 48 (38.1%) and 78 (61.9%) of medication errors, respectively. Conclusions: MEs occur in all steps of drug therapy, including prescription, dispensing, preparation, transcription and administration, causing a great concern for hospitalized patients. Strict controlling and training programs for medical students and nurses regarding rational use and prescription of drugs, and presence of clinical pharmacists in the medical wards are highly recommended for preventing these types of errors.
Collections
Related items
Showing items related by title, author, creator and subject.
-
A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006-2016)
Montazeri, M; Sharif, M; Sarvi, S; Mehrzadi, S; Ahmadpour, E; Daryani, A (2017)The currently available anti-Toxoplasma agents have serious limitations. This systematic review was performed to evaluate drugs and new compounds used for the treatment of toxoplasmosis. Data was systematically collected ... -
Pharmacological effects of ?-D-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-?B gene expression, as target molecules in inflammatory reactions
Mortazavi-Jahromi, SS; Jamshidi, MM; Farazmand, A; Aghazadeh, Z; Yousefi, M; Mirshafiey, A (2017)Background Impaired expression and function of microRNAs (miRNAs) are involved in the pathogenesis of many autoimmune and inflammatory diseases. Moreover, there is a close relationship between TLRs and miRNAs and impairment ... -
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRAآ®) to the reference product (Humiraآ®) in patients with active rheumatoid arthritis
Jamshidi, A; Gharibdoost, F; Vojdanian, M; Soroosh, SG; Soroush, M; Ahmadzadeh, A; Nazarinia, MA; Mousavi, M; Karimzadeh, H; Shakibi, MR; Rezaieyazdi, Z; Sahebari, M; Hajiabbasi, A; Ebrahimi, AA; Mahjourian, N; Rashti, AM (2017)Background: This study aimed to compare efficacy and safety of test-adalimumab (CinnoRAآ®, CinnaGen, Iran) to the innovator product (Humiraآ®, AbbVie, USA) in adult patients with active rheumatoid arthritis (RA). Methods: ...